Recurrent Multiple Myeloma


Farydak® Approval Provides Another Treatment Option for Patients With Multiple Myeloma (02-25-2015)

Novartis announced today that the US Food and Drug Administration (FDA) has approved Farydak® (panobinostat) in combination with Velcade® and dexamethasone for the treatment of patients with multiple myeloma who have received at least two prior regimens,... Continue Reading

Further Findings Show Pomalyst plus Low-Dose Dexamethasone Safe and Effective in Relapsed or Refractory Multiple Myeloma (01-26-2015)

For patients with relapsed or refractory multiple myeloma, treatment with Pomalyst® (pomalidomide) plus low-dose dexamethasone appears safe and effective. These findings were presented at the 56th American Hematological Society Annual Meeting and Exposition,... Continue Reading

Daratumumab Anti-CD38 Monoclonal Antibody Appears Promising For the Treatment of Multiple Myeloma (12-15-2014)

An investigational new class of drugs, the anti-CD38 monoclonal antibodies, could be the next major advance in the treatment of multiple myeloma. These findings were presented at the 56th American Hematological Society Annual Meeting and Exposition, December... Continue Reading

Imbruvica® Demonstrates Clinical Activity in Relapsed or Refractory Multiple Myeloma (12-10-2014)

According to new data reported at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition, Imbruvica® (ibrutinib) demonstrated activity in the treatment of patients with relapsed or relapsed/refractory multiple myeloma. Multiple myeloma... Continue Reading

SAR 650948 Anti-CD38 Monoclonal Antibody Appears Promising For the Treatment of Multiple Myeloma (12-9-2014)

An investigational new class of drugs, the anti-CD38 monoclonal antibodies, could be the next major advance in the treatment of multiple myeloma. These findings were presented at the 56th American Hematological Society Annual Meeting and Exposition, December... Continue Reading

ASH 2014: Kyprolis®-Based Treatment Demonstrates Significant Advance in the Treatment of Multiple Myeloma (12-7-2014)

Results of the phase 3 clinical trial ASPIRE were presented at the American Society of Hematology Meetings this week. Relapsed multiple myeloma patients treated with Kyprolis® (carfilzomib) in combination with Revlimid® (lenalidomide) and low-dose dexamethasone... Continue Reading

Adding Pan-Deacetylase Inhibitor Panobinostat to Velcade and Dexamethasone Improves Progression-Free Survival in Relapsed Myeloma (11-5-2014)

In the phase III PANORAMA1 trial reported in The Lancet Oncology San-Miguel and colleagues found that adding the pan-deacetylase inhibitor panobinostat to Velcade ® (bortezomib) and dexamethasone improved progression-free survival in patients with relapsed... Continue Reading

Velcade Approved for Retreatment in Multiple Myeloma (08-21-2014)

The U.S. Food and Drug Administration (FDA) has approved Velcade® (bortezomib) for the retreatment of adult patients with multiple myeloma who had previously responded to Velcade therapy and relapsed at least six months following completion of prior... Continue Reading

Kyprolis Improves Progression-Free Survival in Multiple Myeloma (08-7-2014)

Amgen announced that a planned interim analysis demonstrated that the Phase 3 clinical trial ASPIRE met its primary endpoint of progression-free survival (PFS).  Patients treated with Kyprolis® (carfilzomib) in combination with Revlimid® (lenalidomide)... Continue Reading

Elotuzumab Earns U.S. Food and Drug Administration Breakthrough Therapy Designation for Multiple Myeloma (05-26-2014)

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to the drug elotuzumab for use in previously treated, or relapsed, multiple myeloma. This announcement was recently made in a press release from drug-maker Bristol-Myers... Continue Reading

« Previous PageNext Page »